Earnings Call Summary | Electromed(ELMD.US) Q3 2024 Earnings Conference
Earnings Call Summary | Electromed(ELMD.US) Q3 2024 Earnings Conference
The following is a summary of the Electromed, Inc. (ELMD) Q3 2024 Earnings Call Transcript:
以下是Electromed, Inc.（ELMD）2024年第三季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Electromed reported Q3 2024 net revenue of $13.9 million, a growth of 15% YoY, and quarterly earnings of $1.5 million or $0.17 per diluted share.
Q3 2024 operating income was $1.8 million, up by 54% from the same period in the last fiscal year.
The company saw an increase in homecare revenue, hospital revenue, and homecare distributor revenue in Q3 2024.
Electromed maintains a healthy financial state, being debt-free with cash and equivalents worth $11.7 million at the end of Q3 2024.
Electromed報告稱，2024年第三季度淨收入爲1,390萬美元，同比增長15％，季度收益爲150萬美元，攤薄後每股收益爲0.17美元。
2024年第三季度的營業收入爲180萬美元，較上一財年同期增長54％。
該公司在2024年第三季度實現了家庭護理收入、醫院收入和家庭護理分銷商收入的增長。
Electromed保持健康的財務狀況，到2024年第三季度末沒有債務，現金及等價物價值1170萬美元。
Business Progress:
業務進展：
Electromed expanded its sales team in Q3 2024, driving further market penetration and supporting a larger pool of physician prescribers.
The company was recognized as the Corporate Partner of the Year by the California Society of Respiratory Care.
New educational resources have been launched with the goal of creating more awareness among providers about the benefits of using their technology in treating bronchiectasis patients.
The company has successfully mitigated the impact of a cyber attack on Change Healthcare, with 98% of delayed claims submissions resolved.
A new ERP system has been implemented that provides improved operational and financial insights.
Improved productivity within the reimbursement team has led to better leverage within the company's P&L.
Electromed is capable of attracting great talent due to their financial success and company culture.
The company continues to see upward trajectory with consistent growth and improved profitability, aligning with their goal of optimizing long-term shareholder value.
Electromed在2024年第三季度擴大了銷售團隊，進一步推動了市場滲透率，併爲更多的醫生處方者提供了支持。
該公司被加州呼吸護理學會評爲年度企業合作伙伴。
已經推出了新的教育資源，目的是提高提供者對使用其技術治療支氣管擴張患者的益處的認識。
該公司成功減輕了網絡攻擊對Change Healthcare的影響，98％的延遲索賠申請已得到解決。
已經實施了新的ERP系統，該系統提供了更好的運營和財務洞察力。
報銷團隊工作效率的提高提高了公司損益中的槓桿作用。
由於他們的財務成功和公司文化，Electromed能夠吸引優秀的人才。
該公司繼續保持上升軌跡，持續增長並提高盈利能力，這與優化長期股東價值的目標一致。
More details: Electromed IR
更多詳情： 電磁紅外
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。